Ahizechukwu C Eke1, Alice M Stek2, Jiajia Wang3, Regis Kreitchmann4, David E Shapiro3, Elizabeth Smith5, Nahida Chakhtoura6, Edmund V Capparelli7, Mark Mirochnick8, Brookie M Best7. 1. Division of Maternal Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD. 2. Department of Obstetrics and Gynecology, University of Southern California School of Medicine, Los Angeles, CA. 3. Department of Biostatistics, Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA. 4. HIV/AIDS Research Department, Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, SR, Brazil. 5. Pediatric Medicine Research Branch, National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD. 6. Maternal and Pediatric Infectious Disease Branch, National Institute of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Bethesda, MD. 7. Department of Clinical Pharmacy and Pediatrics, University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, CA. 8. Division of Neonatology, Department of Pediatrics, Boston University School of Medicine, Boston, MA; and.
Abstract
BACKGROUND: This study aims to evaluate the pharmacokinetics of an increased dose of darunavir (800 mg twice daily) with 100 mg ritonavir during pregnancy and postpartum. METHODS: Darunavir (DRV) and ritonavir (RTV; r) intensive pharmacokinetic evaluations were performed at steady state during the second and third trimesters of pregnancy (DRV/r 800/100 mg bid) and 2-3 weeks postpartum (DRV/r 600/100 mg twice daily). Plasma concentrations of darunavir and ritonavir were measured using high-performance liquid chromatography. Target darunavir area under the concentration time curve (AUC) was >70% (43.6 μg × h/mL) of median AUC (62.3 μg × h/mL) in nonpregnant adults on twice daily darunavir-ritonavir 600/100 mg. RESULTS: Twenty-four women were included in the analysis. Darunavir AUC0-12 was lower with the increased dose during the second {[geometric mean ratio (GMR) of 0.62 (IQR 0.44-0.88); P = 0.055]} and third trimesters [GMR 0.64 (IQR 0.55-0.73); P = <0.001] compared with postpartum. Darunavir apparent clearance was higher during the second [GMR 1.77 (IQR 1.24-2.51); P = 0.039] and third trimesters [GMR 2.01 (IQR 1.17-2.35); P = <0.001] compared with postpartum. Similarly, ritonavir AUC0-12 was lower during the third trimester [GMR 0.65 (IQR 0.52-0.82); P = 0.007] compared with postpartum, whereas its apparent clearance was higher during the third trimester [GMR 1.53 (IQR 1.22-1.92); P = 0.008] compared with postpartum. No major drug-related safety concerns were noted. CONCLUSIONS: Increasing darunavir dose to 800 mg BID failed to significantly increase darunavir exposure compared with 600 mg BID. Other strategies, such as increasing the ritonavir dose should be investigated.
BACKGROUND: This study aims to evaluate the pharmacokinetics of an increased dose of darunavir (800 mg twice daily) with 100 mg ritonavir during pregnancy and postpartum. METHODS: Darunavir (DRV) and ritonavir (RTV; r) intensive pharmacokinetic evaluations were performed at steady state during the second and third trimesters of pregnancy (DRV/r 800/100 mg bid) and 2-3 weeks postpartum (DRV/r 600/100 mg twice daily). Plasma concentrations of darunavir and ritonavir were measured using high-performance liquid chromatography. Target darunavir area under the concentration time curve (AUC) was >70% (43.6 μg × h/mL) of median AUC (62.3 μg × h/mL) in nonpregnant adults on twice daily darunavir-ritonavir 600/100 mg. RESULTS: Twenty-four women were included in the analysis. Darunavir AUC0-12 was lower with the increased dose during the second {[geometric mean ratio (GMR) of 0.62 (IQR 0.44-0.88); P = 0.055]} and third trimesters [GMR 0.64 (IQR 0.55-0.73); P = <0.001] compared with postpartum. Darunavir apparent clearance was higher during the second [GMR 1.77 (IQR 1.24-2.51); P = 0.039] and third trimesters [GMR 2.01 (IQR 1.17-2.35); P = <0.001] compared with postpartum. Similarly, ritonavir AUC0-12 was lower during the third trimester [GMR 0.65 (IQR 0.52-0.82); P = 0.007] compared with postpartum, whereas its apparent clearance was higher during the third trimester [GMR 1.53 (IQR 1.22-1.92); P = 0.008] compared with postpartum. No major drug-related safety concerns were noted. CONCLUSIONS: Increasing darunavir dose to 800 mg BID failed to significantly increase darunavir exposure compared with 600 mg BID. Other strategies, such as increasing the ritonavir dose should be investigated.
Authors: P Kuehl; J Zhang; Y Lin; J Lamba; M Assem; J Schuetz; P B Watkins; A Daly; S A Wrighton; S D Hall; P Maurel; M Relling; C Brimer; K Yasuda; R Venkataramanan; S Strom; K Thummel; M S Boguski; E Schuetz Journal: Nat Genet Date: 2001-04 Impact factor: 38.330
Authors: Mark Mirochnick; Brookie M Best; Alice M Stek; Edmund V Capparelli; Chengcheng Hu; Sandra K Burchett; Steven S Rossi; Elizabeth Hawkins; Michael Basar; Elizabeth Smith; Jennifer S Read Journal: J Acquir Immune Defic Syndr Date: 2011-04-15 Impact factor: 3.731
Authors: Erkki Lathouwers; Sandra De Meyer; Inge Dierynck; Tom Van de Casteele; Ludo Lavreys; Marie-Pierre de Béthune; Gaston Picchio Journal: Antivir Ther Date: 2011
Authors: H M Crauwels; T N Kakuda; B Ryan; C Zorrilla; O O Osiyemi; S Yasin; K Brown; P Verboven; V Hillewaert; B Baugh Journal: HIV Med Date: 2016-05-17 Impact factor: 3.180
Authors: Keikawus Arastéh; Patrick Yeni; Anton Pozniak; Beatriz Grinsztejn; Dushyantha Jayaweera; Afsoon Roberts; Jennifer Hoy; Sandra De Meyer; Tony Vangeneugden; Frank Tomaka Journal: Antivir Ther Date: 2009
Authors: Erkki Lathouwers; Guy De La Rosa; Tom Van de Casteele; Benny Baeten; Frank Tomaka; Sandra De Meyer; Gaston Picchio Journal: Antivir Ther Date: 2013-04-04
Authors: Richard Haubrich; Dan Berger; Philippe Chiliade; Amy Colson; Marcus Conant; Joel Gallant; Timothy Wilkin; Jeffrey Nadler; Gerald Pierone; Michael Saag; Ben van Baelen; Eric Lefebvre Journal: AIDS Date: 2007-03-30 Impact factor: 4.177
Authors: Ahizechukwu C Eke; Kristina M Brooks; Rahel D Gebreyohannes; Jeanne S Sheffield; Kelly E Dooley; Mark Mirochnick Journal: Expert Opin Drug Metab Toxicol Date: 2020-03-17 Impact factor: 4.936
Authors: Ahizechukwu C Eke; Adeniyi Olagunju; Brookie M Best; Mark Mirochnick; Jeremiah D Momper; Elaine Abrams; Martina Penazzato; Tim R Cressey; Angela Colbers Journal: Clin Pharmacokinet Date: 2020-10 Impact factor: 6.447